TY - JOUR
T1 - C-KIT mutation role in oral malignant melanoma pathway
T2 - A narrative review
AU - Gofur, Nanda Rachmad Putra
AU - Gofur, Aisyah Rachmadani Putri
AU - Putri, Hernalia Martadila
N1 - Publisher Copyright:
© 2021 Journal of International Oral Health Published by Wolters Kluwer - Medknow.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Aim: To investigate the role of the c-KIT mutation in oral malignant melanoma (OMM). Materials and Methods: The search strategy includes randomized control trials and clinical trials from the databases of PubMed Central, Cochrane, EBSCO, and MEDLINE from January 1999 to May 2019. A total of seven clinical trials that met all inclusion criteria were included in this systematic review. Results: A previous study found that c-KIT can initiate the activation variety of downstream pathways, including the MAPK/MEK and PI3K/AKT pathways, which play important roles in cancer development. The c-KIT mutation has resulted in a loss of heterozygosity at 12p13, and loss of p27KIP1 protein has been detected. Activating c-KIT mutations in the juxtamembrane and other domains has been considered as an oncogene and also a therapeutic target in various tumors. Conclusion: c-KIT is playing the role of an important target in the research of molecular therapy in patients with metastatic OMM with c-KIT mutations.
AB - Aim: To investigate the role of the c-KIT mutation in oral malignant melanoma (OMM). Materials and Methods: The search strategy includes randomized control trials and clinical trials from the databases of PubMed Central, Cochrane, EBSCO, and MEDLINE from January 1999 to May 2019. A total of seven clinical trials that met all inclusion criteria were included in this systematic review. Results: A previous study found that c-KIT can initiate the activation variety of downstream pathways, including the MAPK/MEK and PI3K/AKT pathways, which play important roles in cancer development. The c-KIT mutation has resulted in a loss of heterozygosity at 12p13, and loss of p27KIP1 protein has been detected. Activating c-KIT mutations in the juxtamembrane and other domains has been considered as an oncogene and also a therapeutic target in various tumors. Conclusion: c-KIT is playing the role of an important target in the research of molecular therapy in patients with metastatic OMM with c-KIT mutations.
KW - c-KIT Mutation
KW - OMM
KW - Oral Lesion
KW - Pathway
UR - http://www.scopus.com/inward/record.url?scp=85117930013&partnerID=8YFLogxK
U2 - 10.4103/JIOH.JIOH_6_21
DO - 10.4103/JIOH.JIOH_6_21
M3 - Review article
AN - SCOPUS:85117930013
SN - 0976-7428
VL - 13
SP - 429
EP - 434
JO - Journal of International Oral Health
JF - Journal of International Oral Health
IS - 5
ER -
